^
    1d
    The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trial. (PubMed, Cancer Res Commun)
    Possible lower LRF and less acute toxicity with cetuximab versus cisplatin for KRAS-variant patients appear to be offset by potentially increased late toxicity. Further evaluation of this class of biomarkers is warranted.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Erbitux (cetuximab) • cisplatin
    2d
    Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=290, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • fluorouracil topical
    2d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    3d
    A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date • Minimal residual disease
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • NavDx®
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    3d
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    3d
    TARGET-HPV: TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (clinicaltrials.gov)
    P1/2, N=98, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel
    3d
    TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Emory University | N=12 --> 40 | Trial completion date: Jan 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Enrollment change • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Keytruda (pembrolizumab)
    3d
    NRG-HN005: De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2/3, N=384, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
    4d
    Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    cisplatin • bemcentinib (BGB324) • TheraCIM (nimotuzumab)
    4d
    NRG-HN009: Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P2/3, N=1714, Suspended, NRG Oncology | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    cisplatin
    5d
    VELOCITY-HNSCC: Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • paclitaxel • Yutuo (zimberelimab) • domvanalimab (AB154)
    5d
    Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (clinicaltrials.gov)
    P3, N=454, Not yet recruiting, NRG Oncology
    New P3 trial
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel